TEL1 Stock Overview
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for TEL1 from our risk checks.
Sihuan Pharmaceutical Holdings Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.058 |
| 52 Week High | HK$0.099 |
| 52 Week Low | HK$0.056 |
| Beta | 0.68 |
| 1 Month Change | -6.45% |
| 3 Month Change | -8.66% |
| 1 Year Change | -33.33% |
| 3 Year Change | -82.10% |
| 5 Year Change | -75.00% |
| Change since IPO | -78.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| TEL1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.8% | 2.3% | 0.5% |
| 1Y | -33.3% | -28.6% | 1.3% |
Return vs Industry: TEL1 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: TEL1 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| TEL1 volatility | |
|---|---|
| TEL1 Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TEL1 has not had significant price volatility in the past 3 months.
Volatility Over Time: TEL1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,872 | Weicheng Guo | www.sihuanpharm.com |
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. It offers drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing.
Sihuan Pharmaceutical Holdings Group Ltd. Fundamentals Summary
| TEL1 fundamental statistics | |
|---|---|
| Market cap | €596.86m |
| Earnings (TTM) | -€6.96m |
| Revenue (TTM) | €239.58m |
2.5x
P/S Ratio-85.8x
P/E RatioIs TEL1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEL1 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.86b |
| Cost of Revenue | CN¥564.90m |
| Gross Profit | CN¥1.30b |
| Other Expenses | CN¥1.35b |
| Earnings | -CN¥54.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0058 |
| Gross Margin | 69.64% |
| Net Profit Margin | -2.90% |
| Debt/Equity Ratio | 22.9% |
How did TEL1 perform over the long term?
See historical performance and comparison